135 related articles for article (PubMed ID: 38665038)
21. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.
Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X
Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153
[TBL] [Abstract][Full Text] [Related]
22. Access to molecular guided therapy for Langerhans cell histiocytosis patients.
Charles J; Beani JC; Tardieu M; Busser B
J Am Acad Dermatol; 2015 Jul; 73(1):e31. PubMed ID: 26089071
[No Abstract] [Full Text] [Related]
23. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
24. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
Evseev D; Osipova D; Kalinina I; Raykina E; Ignatova A; Lyudovskikh E; Baidildina D; Popov A; Zhogov V; Semchenkova A; Litvin E; Kotskaya N; Cherniak E; Voronin K; Burtsev E; Bronin G; Vlasova I; Purbueva B; Fink O; Pristanskova E; Dzhukaeva I; Erega E; Novichkova G; Maschan A; Maschan M
Blood Adv; 2023 Sep; 7(18):5246-5257. PubMed ID: 37216396
[TBL] [Abstract][Full Text] [Related]
25. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of BRAF-Inhibitor Therapy in BRAF
Hazim AZ; Ruan GJ; Ravindran A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
Oncologist; 2020 Dec; 25(12):1001-1004. PubMed ID: 32985015
[TBL] [Abstract][Full Text] [Related]
27. Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor.
Gandolfi L; Adamo S; Pileri A; Broccoli A; Argnani L; Zinzani PL
J Natl Compr Canc Netw; 2015 Jun; 13(6):715-8. PubMed ID: 26085387
[TBL] [Abstract][Full Text] [Related]
28. Granulomatous dermatitis secondary to vemurafenib in a child with Langerhans cell histiocytosis.
Chen L; Hsi AC; Kothari A; Dehner LP; Hayashi RJ; Coughlin CC
Pediatr Dermatol; 2018 Nov; 35(6):e402-e403. PubMed ID: 30216522
[TBL] [Abstract][Full Text] [Related]
29. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
[TBL] [Abstract][Full Text] [Related]
30. A circulating subset of BRAF
Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
[TBL] [Abstract][Full Text] [Related]
31. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
32. Mixed Langerhans Cell Histiocytosis and Erdheim-Chester Disease in a Girl: A Rare and Puzzling Diagnosis.
Ocak S; Bayramoglu Z; Tugcu D; Karaman S; Unuvar A; Karakas Z
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e375-e379. PubMed ID: 32097280
[TBL] [Abstract][Full Text] [Related]
33. Circulating cell-free
Cui L; Zhang L; Ma HH; Wang CJ; Wang D; Lian HY; Li WJ; Zhang Q; Li N; Wang TY; Li ZG; Zhang R
Haematologica; 2020 Sep; 105(9):e444-447. PubMed ID: 33054060
[No Abstract] [Full Text] [Related]
34. BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis.
Bellinato F; Maurelli M; Colato C; Balter R; Girolomoni G; Schena D
Br J Dermatol; 2019 Apr; 180(4):933-934. PubMed ID: 30430550
[No Abstract] [Full Text] [Related]
35. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the
Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R
Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160
[TBL] [Abstract][Full Text] [Related]
36. Autologous hematopoietic stem cell transplantation for efficient treatment of multisystem, high-risk,
Pan Y; Xi R; Wang C; Fang L; Bai J; Cai Y; Guo M; Qiao R; Lan X; Yin J; Yang K; Bai H
J Int Med Res; 2019 Sep; 47(9):4522-4529. PubMed ID: 31426694
[TBL] [Abstract][Full Text] [Related]
37. New somatic BRAF splicing mutation in Langerhans cell histiocytosis.
Héritier S; Hélias-Rodzewicz Z; Chakraborty R; Sengal AG; Bellanné-Chantelot C; Thomas C; Moreau A; Fraitag S; Allen CE; Donadieu J; Emile JF
Mol Cancer; 2017 Jul; 16(1):115. PubMed ID: 28679432
[TBL] [Abstract][Full Text] [Related]
38. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J
N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849
[TBL] [Abstract][Full Text] [Related]
39. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis.
Karri V; Lin H; Velazquez J; Batajoo A; Parekh D; Stanton W; Abhyankar H; El-Mallawany NK; Agrusa J; Eckstein O; Gulati N; Schwartz J; Woods-Swafford W; Boyd J; Saha A; Allen CE; McClain KL
Br J Haematol; 2024 May; 204(5):1882-1887. PubMed ID: 38501390
[TBL] [Abstract][Full Text] [Related]
40. A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
Arceci RJ; Allen CE; Dunkel IJ; Jacobsen E; Whitlock J; Vassallo R; Morris SR; Portnoy A; Reedy BA; Smith DA; Noble R; Murnane A; Cornfeld M; Rodriguez-Galindo C; Heaney ML; McClain K; Vaiselbuh S
Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27804235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
